

**EXHIBIT 6-e to PLAINTIFFS’  
APPENDIX OF EXPERT REPORTS**

#### **Schedule 4. Additional Materials Considered**

##### **Depositions and Exhibits:**

Kelly Deposition, Dkt. # 1963-14

Russell Portenoy Deposition (01/24/19), Dkt. # 1969-11

Perry Fri Deposition

Rita Norton Deposition exhibit no. 448.

Kathleen Foley Deposition

Melanie Rosenblatt Deposition (05/31/19)

Michael Miller Deposition (06/04/19)

Elizabeth Tatum Deposition (12/11/18)

Burt Rosen Deposition, Dkt. # 1970-10

Alan Must Deposition (3/14/19), Dkt. #1968-13

##### **Articles and Websites:**

1. Tesfaye, N. (2019, May 29). *Associate Companies*. Home National Association of Chain Drug Stores (NACDS). <https://www.nacds.org/membership/directories/associate-companies/>
2. Ornstein, C., & Weber, T. (2012, May 8). senate panel investigates drug companies ties to paingroups. Washington Post. [https://www.washingtonpost.com/national/health-science/senate-panel-investigates-drug-companies-ties-to-paingroups/2012/05/08/gIQA2X4qBU\\_story.html?utm\\_term=.923591ad4d49](https://www.washingtonpost.com/national/health-science/senate-panel-investigates-drug-companies-ties-to-paingroups/2012/05/08/gIQA2X4qBU_story.html?utm_term=.923591ad4d49)
3. <http://archive.jsonline.com/watchdog/watchdogreports/120331689.html/>
4. Model Policy for the Use of Controlled Substances for the Treatment of Pain (2004)
5. Scott Fishman, FSMB Responsible Opioid Prescribing: A Clinician's Guide (2007)
6. Managing Persistent Pain in Older Persons – American Geriatric Society (1998)
7. Management of Persistent Pain in Older Persons-American Geriatric Society (2002)

8. The Pharmacological Management of Pain in Older Persons (2009).
9. Russell K. Portenoy & Kathleen M. Foley, Chronic Use Of Opioid Analgesics In Non-Malignant Pain: Report Of 38 Cases, *Pain* 25.2, 171-186 (1986)
10. Thomas Catan & Evan Perez, A Pain-Drug Champion Has Second Thoughts, *Wall. St. J.* (Dec. 17, 2012), <https://www.wsj.com/articles/SB10001424127887324478304578173342657044604>
11. Fueling and Epidemic, Exposing the Financial Ties Between Opioid Manufacturers and Third Party Advocacy Groups, U.S. Senate Homeland Security and Governmental Affairs Committee, Minority Staff Report (Feb. 2018)
12. Fueling an Epidemic: Exposing the Financial Ties Between Opioid Manufacturers and Third Party Advocacy Groups (Report 2) (<https://www.hsdl.org/?abstract&did=808171>)
13. Fauber, J. (2011, April 10). UW group ends drug firm funds. *The Milwaukee Journal Sentinel*. <http://archive.jsonline.com/watchdog/watchdogreports/120331689.html/>
14. AAPM & APS, The Use of Opioids for the Treatment of Chronic Pain: A consensus statement from the American Academy of Pain Medicine and the American Pain Society, 6 *J. of Pain* 1, 77-79 (1997)
15. Past Presidents, American Academy of Pain Medicine, available at <https://painmed.org/about/board/council-of-past-presidents>, last accessed on July 30, 2019
16. Paula Moyer, The Current State of Pain Management, *MedScape* (2005), <https://www.medscape.org/viewarticle/500829>
17. Corporate Relations Council, American Academy of Pain Medicine, available at <https://painmed.org/about/corporate-support/corporate-relations-council>, last accessed on July 30, 2019; see also, Corporate Relations Council: Striving for Better Patient Care, American Academy of Pain Medicine, available at <https://painmed.org/uploads/about/aapm-corporate-relations-council-brochure.pdf>, last accessed on July 30, 2019
18. <https://www.successfactors.com/content/ssf-site/en/resources/knowledge-hub/educational-articles/jointcommission-compliance.html>
19. Federation of Medical Boards of the United States, Inc., Model Guidelines for the Use of Controlled Substances for the Treatment of Pain (May 2, 1998) (hereinafter “FSMB, Model Guidelines”)

20. Murphy, B. (2017, May 31) For first time, physician practice owners are not the majority. American Medical Association. <https://www.ama-assn.org/practice-management/economics/first-time-physician-practice-owners-are-not-majority>

21. Joint Commission on Accreditation of Healthcare Organizations, Pain Standards for 2001 (2001); [https://www.jointcommission.org/assets/1/6/Pain\\_Std\\_History\\_Web\\_Version\\_05122017.pdf](https://www.jointcommission.org/assets/1/6/Pain_Std_History_Web_Version_05122017.pdf)

**Produced Documents:**

2018-02-05_RP_000221-000741	JAN-MS-00313716
ABDCMDL00169889	JAN-MS-00324305
ABT-MDL-KY-0043299	PDD1701481531
CAH_MDL2804_00886155	PKY181656516
CHC00068828	PPLP003477086
CHI_001715794	PPLP004266177
CHI_001978630	PPLP004299456
CVS-MDLT1-000121577	PPLPC018000050847
E513_00028712	PPLPC022000024918
END00033238	PPLPC02500001258
END00041232	ML00055624
ENDO-CHI_LIT-00247966	JAN-MS-00306713
ENDO-OPIOID_MDL01444991	CAH_MDL2804_00861971
ENDO-OPIOID_MDL01445157	PPLPC024000125469
ENDO-OPIOID_MDL-01445159	PPLPC017000604922
ENDO-OPIOID_MDL-03355279	APS-MDL00000001
ENDO-OPIOID_MDL-03355281	SFC00000001
ENDO-OPIOID_MDL-04669404	CVS-MDLT1-000102930
ENDO-OPIOID_MDL-04669526	WIS_PPSG_008292
ENDO-OPIOID_MDL-04754767	PKY183381048
ENDO-OR-CID-00559762	PPLP003477687
EPI001038487	ENDO-OPIOID_MDL-01444993
EPI001059511	EPI000664622
FSMB0000017	INSYS-MDL003350902
HDA_MDL_000117241	ENDO-OPIOID_MDL-03355280
HDA_MDL_000158258	PPLP004496559
INSYS-MDL-003350902	ENDO-OPIOID_MDL-04669418
INSYS-MDL-006047762	ENDO-OPIOID_MDL-04669540
INSYS-MDL-010473678	EPI000649269
INSYS-MDL-010477468	PPLP003985888
INSYS-MDL-010477473	ENDO-OPIOID_MDL-02212590
JAN-MS-00000001	PPLP004052907
JAN-MS-00247231	PKY182577992

JAN-MS-00262912	HDA_MDL_000117082
JAN-MS-00264548	HDA_MDL_000117141
JAN-MS-00306275	INSYS-MDL-010471732
JAN-MS-00323434	INSYS-MDL-010477470
JAN-MS-00350802	INSYS-MDL-005393278
JAN-MS-00350962	END00735356
JAN-MS-00395592	JAN-MS-00306263
JAN-MS-00395596	JAN-MS-00395603
JAN-MS-00395613	JAN-MS-00395611
JAN-MS-00395630	JAN-MS-00315325
JAN-MS-00409782	JAN-MS-00308836
JAN-MS-00410890	JAN-MS-00314059
JAN-MS-00474421	JAN-MS-00323859
JAN-MS-00828205	JAN-MS-00325962
JAN-MS-00918396	JAN-MS-00393409
JAN-MS-00927589	JAN-MS-00395594
JAN-MS-00928065	JAN-MS-00395599
JAN-MS00938504	JAN-MS-00395614
JAN-MS-01006283	JAN-MS-00264370
JAN-MS-01052128	JAN-MS-01239356
JAN-MS-01052165	JAN-MS-00474423
JAN-MS-01052181	JAN-MS-00408422
JAN-MS-01151875	JAN-MS-00949290
JAN-MS-02659095	JAN-MS-00932379
JAN-MS-03089430	JAN-MS-00928067
JAN-MS-04290083,	JAN-MS-00925643
MNK-T1_0005823847	JAN-MS-00246903
MNK-T1_0008005740	JAN-MS-00456087
PDD8801161604	JAN-MS-00456093
PDD8801201589	JAN-MS-01051754
PDD8801293266	JAN-MS-00427861
PKY180481336	JAN-MS-04290087
PKY180770966	PDD8801320902
PKY180790274	PDD1701853088
PKY181058664	PKY180772092
PKY181128168	PDD1701553475
PKY181221797	PPLPC013000032704
PKY182620813	ENDO-OPIOID_MDL-01610298
PKY182717470	PLTF_2804_000013560
PPLP003892671	PDD1701260996
PPLP004065294	PKY180784295
PPLP004081148	APS-MDL00000005
PPLP004272094	JAN-MS-00313199
PPLP004303706	JAN-MS-00312347

PPLPC005000220230	PPLPC025000005629
PPLPC011000093410	CHI_002300587
PPLPC011000093411	PPLPC019001182680
PPLPC017000347668	PPLP004266519
PPLPC017000683105	PPLP004051807
PPLPC019000247613	ENDO-OPIOID_MDL-01412623
PPLPC019000632316	PPLPC018001287703
PPLPC019001239393	PPLPC005000220232
PPLPC020000005715	PPLPC019000632314
PPLPC021000028121	PPLPC017000687083
PPLPC021000071400	JAN-MS-02494558
PPLPC023000039492	PPLP004282881
PPLPC023000876706	ENDO-OPIOID_MDL-01445020
PPLPC037000008901	PPLPC018000617695
PPLPC045000004928	PPLPC009000019931
PPLPC051000064077	PDD8801291781
TEVA_MDL_A_05508891	PPLPC021000028122
WIS_Joranson_000071	PPLPC021000222248
WIS_PPSG_000026	TEVA_MDL_A_0550903905508891
WIS_PPSG_005251	PPLPC023000876707
WIS_PPSG_006938	JAN-MS-00307337
WIS_PPSG_008286	PPLPC012000065091
PKY180470186	PPLPC037000007677
WIS_PPSG_000036	PPLPC022000045283
CHI_00443601	EPI000066634
PKY181678252	TEVA_MDL_A_05508908-8909